Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Fistula × Clear all

Phase

Status

Completed 5 Unknown 2 Recruiting 2 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 380 Neoplasms 266 Carcinoma, Non-Small-Cell Lung 211 Prostatic Neoplasms 204 Colorectal Neoplasms 142 Lung Neoplasms 137 Pancreatic Neoplasms 121 Neoplasm Metastasis 120 Leukemia, Myeloid, Acute 119 Carcinoma, Hepatocellular 110 Multiple Myeloma 106 Lymphoma 101 Melanoma 92 Head and Neck Neoplasms 91 Ovarian Neoplasms 90 Brain Neoplasms 86 Recurrence 82 Leukemia, Lymphocytic, Chronic, B-Cell 77 Leukemia 77 Glioblastoma 75 Colonic Neoplasms 71 Precursor Cell Lymphoblastic Leukemia-Lymphoma 68 Squamous Cell Carcinoma of Head and Neck 67 Lymphoma, Non-Hodgkin 65 Carcinoma, Renal Cell 62 Lymphoma, Follicular 58 Hematologic Neoplasms 57 Lymphoma, Large B-Cell, Diffuse 56 Rectal Neoplasms 54 Stomach Neoplasms 50

Interventions

Certolizumab Pegol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

Data powered by HemOnc (CC BY 4.0) Colophon ⚡